ABSTRACT This manuscript describes an enantioselective synthesis of cephalostatin 1. Key steps of this synthesis are a unique methyl group selective allylic oxidation, directed C-H hydroxylation of a sterol at C12, Au(I)-catalyzed 5-endo-dig cyclization and a kinetic spiroketalization.
Introduction
An important property of modern anti-cancer therapeutics is the selective killing of cancer cells over normal cells. One approach to achieve selectivity is "synthetic lethality," 1 involving combination of a mutation, only present in cancer cells, and a small molecule, resulting in selective cell killing of the cells bearing the mutation. Since many genetic mutations have been identified in tumor cells, a challenge is to discover small molecules that selectively target cells harboring these mutations.
We have become interested in the therapeutic potential and cellular target of cephalostatin 1 (1), a natural product that may be synthetic lethal with the p16 tumor suppressor gene. In a bioinformatics comparison of the cytotoxicity profiles of ~43,000 small molecules with cell lines bearing altered p16, 1 emerged as the compound with the highest correlation, suggesting that it may be selectively cytotoxic to cells with altered p16. 2 The p16 gene encodes cyclin-dependent kinase inhibitor 2A (CDKN2A or Ink4a), a tumor suppressor protein that blocks cell proliferation by binding to and inhibiting the kinase activity of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6). 2 In cells, both CDK4 and CDK6 each form active complexes with cyclin D that phosphorylate Rb (the retinoblastoma protein), allowing progression through the G1-S phase of the cell cycle. If CDKN2A is inactive due to a mutation or lack of expression, tumor cells can progress uncontrollably through the G1-S phase of the cell cycle. 3 Since p16 is among the most frequently mutated genes in human tumor cells, 1 may be a uniquely selective anti-cancer therapeutic, and elucidation of its unknown cellular target may reveal new ways to achieve synthetic lethality with small molecules.
Cephalostatin 1 was first reported in 1988 as a potent growth inhibitory marine natural product. 4 The average GI 50 of 1 against the NCI-60, a collection of 60 human cancer cell lines, is 1.8 nM. 5 Three other molecules, ritterazine B (2), 6 OSW-1 (3) 7 and schweinfurthin A (4) 8 have cytotoxicity patterns resembling 1, suggesting that all three compounds share similar mechanisms. 9 The cellular target and mechanism of 1 (or 2-4) has not been elucidated, although an increasing amount of research is being focused on these issues.
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The unusually large and complex structure of 1 has been the target of many synthesis studies, with one synthesis reported by Fuchs. 11 Due to the small quantities of 1 available from natural sources, only through synthesis will sufficient amounts of 1 (and analogs) be available to address questions surrounding its potential synthetic lethality with p16, elucidation of its cellular target and mechanism, and determination of its efficacy in vivo. This manuscript reports our synthesis of 1 (Figure 1 ), enabling us to answer the questions posed above surrounding its biological activity. 
Synthesis of the western half of cephalostatin 1 (5).
Our synthesis plan involved construction of the eastern and western portions of 1, followed by unsymmetrical pyrazine formation following the reactions developed by Heathcock 12 and Fuchs.
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The C22 spiroketal of 5 (Scheme 1) is in a thermodynamically favorable configuration, meaning that its stereochemistry can be established by acid-catalyzed equilibration. 14 Hecogenin acetate (6), an inexpensive plant-derived steroid that is available in kilogram quantities, 15 is used as the starting material for our synthesis of the western half since it has handles for most of the functionality of 5, especially oxygenation at C12. Compound 6 was also used by others for their synthesis studies on 1.
With 6 as a starting point for synthesis of 5, we need to rearrange the spiroketal, oxidize C23, deoxygenate C16, install a C14-C15 olefin, and most challenging, oxidize the unactivated C18 angular methyl group (see Scheme 1). Our plan was to generate lumihecogenin acetate (7) by photolysis of 6, a reaction first described by Bladon. 16 Selective oxidation of C18 of 7 to generate 8 followed by Prins cyclization would deliver 9. Compound 9 would then be converted to 5. We recognized that 7 is the only intermediate in our synthesis in which C18 is activated (allylic), and therefore we focused on methods to selectively oxidize the allylic methyl group. This is a significant challenge since the olefin of 7 is tetrasubstituted and there are four other allylic hydrogens (see blue H's), two methines and one methylene. We require an oxidation that is selective for the C18 methyl group and tolerant of highly hindered double bonds, boundary conditions that exclude many of the known allylic oxidation reactions. [O]
spiroketal reorganization
The synthesis of 5 begins with the known conversion of 6 to 7 (Scheme 2). 16 Attempts to perform allylic oxidation of C18 on either aldehyde 7 or the protected alcohol at C18 were unsuccessful. As Ultimately, an unusual allylic oxidation of C18 was achieved. It was discovered that treatment of 7 with 4-phenyl-1,2,4-triazoline-3,5-dione (PTAD, 10), a potent eneophile, lead directly to 11 achieving selective functionalization of the C18 methyl group. Selective activation of the C18 methyl, via an apparent ene reaction, combined with formation of a seven-membered aminal. This transformation may in fact be directed by the C12 aldehyde since the corresponding C12 dimethyl acetal reacted to form a PTAD adduct with abstraction of a C15 proton. One explanation for the selective activation of C18 in this reaction involves initial formation of a zwitterionic adduct (18) between PTAD (10) and aldehyde 7 (Scheme 3). This species could participate in an intramolecular aza-Prins reaction via intermediate 19.
Close proximity between the C12 alkoxide and the C18 methyl group in 19 could explain the selective proton abstraction at C18. Alternatively, PTAD could add to the C12 aldehyde via its carbonyl and engage in an ene reaction, although inspection of molecular models appears to preclude this mechanism due to lack of required orbital overlap. Finally, an ene reaction may occur between 10 and 7 followed by hemiaminal formation.
Treatment of 11 with sodium acetate induced opening of the hemiaminal followed by apparent [2, 3] sigmatropic rearrangement, affording allylic N-Ph urazole 12 (Scheme 3). Protection of the C12 aldehyde as its dimethyl acetal was followed by oxygenation of C18 by treatment of 13 with PhI(OAc) 2 , affording aldehyde 14. In this reaction, the N-N bond is oxidized to N=N. Tautomerization, addition of water, and release of the urazole affords 14. Allylation of the primary hydroxyl group, followed by acid catalyzed acetal hydrolysis set the stage for C-ring closure which was accomplished by treatment with BF 3 ⋅OEt 2 (Scheme 2). Finally, acetylation of the secondary alcohol provided 17. Since the spiroketal of 5 is known to be under thermodynamic control, we expected mild acid treatment of 28 to furnish the F-ring while establishing the desired (S)-stereochemistry at C20.
However, in the presence of camphorsulfonic acid, 28 cyclized to give a spiroketal with 20-(R) stereochemistry. Surprisingly, the observed product results from protonation of the more hindered concave face of the dihydropyran E-ring. This result is in contrast to a similar reaction reported by Fuchs in which protonation of a compound closely related to 28 (except that the C14-C15 double bond was saturated) afforded the desired C20-(S) stereochemistry. 
Synthesis of the cephalostatin 1 eastern half (31).
The E and F rings of the eastern half of cephalostatin 1 consist of a 5,5-spiroketal in a thermodynamically unfavorable configuration at C22 requiring kinetic control for its formation (Scheme 5, 31). The spiroketal in the natural C22-(S) configuration exhibits a single anomeric effect, while the unnatural C22-(R) configuration permits additional stabilization due to a second anomeric effect. To form the 5,5-spiroketal, we planned to induce cyclopropane opening on 32 concurrent with irreversible attack by the C25 hydroxyl group on the less hindered β-face of the incipient oxonium ion, which would simultaneously give rise to the desired configurations of both the C22 spiroketal and the C21 methyl group. Rather than starting with hecogenin acetate (6) to make use of its C12 oxygenation as for the western half of 1, we thought it more expedient to hydroxylate the C12 position of the steroid transandrosterone (34) by a remote C-H oxidation process (see Scheme 5, 34). To increase convergency of the synthesis of 32, the remote oxidation of 34 would be followed by Sonogashira cross coupling with alkyne 33, which comprises seven of the eight carbons of the E,F-rings spiroketal. Our synthesis of alkyne 33 began with the known diol 35 (two steps from 3-methyl-3-buten-1-ol, 89%
yield, 96% ee). 18 We protected the primary hydroxyl as a TBDPS ether, removed the PMP group by 24 however, the undesired C22-(R) spiroketal stereoisomer was favored by a 13:1 ratio. This may be due to HCl generated during the reaction and attempts to buffer the reaction with nitrogenous bases inhibited spiroketalization. We later discovered that oxidative spiroketalization using NBS in THF furnished a separable mixture of bromomethylene spiroketals favoring the desired C22-(S) isomer 49 by a 5:1 ratio. Lack of equilibration in this reaction is due to the neutral reaction conditions. Debromination of 49 by Bu 3 SnH/AIBN followed by silylation of the extremely hindered C17 hydroxyl using neat pyridine/TMSOTf delivered 50 in 65% yield from 49. Selective hydrolysis of the C3 acetate (the C12 acetate is shielded by the C17 OTMS group) followed by Brown-modified Jones oxidation 25 provided 31, the eastern half of cephalostatin 1, in 88% yield over two steps.
Completion of a synthesis of cephalostatin 1.
To prepare the A rings of western half 5 and eastern half 31 for pyrazine coupling, we used a In conclusion, an enantioselective synthesis of cephalostatin 1 has been achieved. In the course of our synthesis of the western half, a unique methyl group-selective allylic oxidation was developed. PTAD underwent selective functionalization of the C18 methyl group, apparently directed by a proximal aldehyde. Subsequent [2, 3] -sigmatropic rearrangement and oxidative hydrolysis of the resulting urazole led to a C18 aldehyde that could not be produced using other methods. This allylic functionalization sequence may be useful in other systems where conventional methods fail. Key steps in the eastern half synthesis include a remote C-H hydroxylation of C12, Sonogashira coupling between a steroid-derived vinyl triflate and an alkyne containing most of the atoms of the E and F rings, a Au(I)-catalyzed 5-endodig cyclization, and a kinetic spiroketalization by cyclopropane ring opening. Our goal is to uncover the cellular target of cephalostatin 1 and explore its therapeutic potential. This synthesis is a first step toward achieving these goals.
